Johnson & Johnson (JNJ) vs Eli Lilly and Company (LLY)
See how Johnson & Johnson and Eli Lilly and Company differ across market data and performance, so you can decide which asset best fits your strategy.
$253.04
NYSE
Johnson & Johnson is the world’s largest and most diversified healthcare company. Its operations are organized into two segments: Innovative Medicine and MedTech, which together account for all revenue following the 2023 separation of its consumer health business, Kenvue. After restructurings completed in 2023 and 2024, the pharmaceutical segment is focused on three core therapeutic areas: immunology, oncology, and neurology. From a geographic perspective, slightly more than half of the company’s total revenue comes from the United States.
Eli Lilly & Co. is a pharmaceutical company focused on neuroscience, cardiometabolic disease, oncology, and immunology. Its leading products include Verzenio and Jaypirca in cancer treatment; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin in cardiometabolic care; and Taltz and Olumiant in immunology.